Is Wegovy a Daily Injection — or Is It Weekly?

Why do people think Wegovy might be daily?

It is a fair assumption. Many familiar medicines (from blood-pressure tablets to vitamin supplements) follow a daily rhythm, so weekly injections feel unusual. There is also some confusion between Wegovy and Ozempic: both contain semaglutide, but Ozempic is licensed for type 2 diabetes, not weight management, and some people conflate the two products when searching. Once you understand the mechanism, the weekly interval makes clinical sense. Semaglutide has a long half-life in the body, roughly one week, which means a single weekly injection sustains therapeutic levels throughout the seven days. If you are curious about how a daily semaglutide injection would compare, the short answer is that it would not add benefit and would almost certainly increase side effects. The NHS semaglutide medicines page confirms the once-weekly schedule and is the clearest plain-English reference if you want to read the dosing framework for yourself.

The short version: one injection, once a week, same day each time. For a fuller explanation of whether Wegovy is a daily or weekly injection, including the reasoning behind the schedule, that page covers the question in detail.

What does the titration schedule actually look like?

Treatment does not start at the full maintenance dose. The prescriber begins at 0.25 mg, a tolerability step designed to let the body adjust before the dose increases. After roughly four weeks, the dose moves to 0.5 mg, then to 1.0 mg, then 1.7 mg, and finally to 2.4 mg, with approximately four weeks at each level. The pace is guided by how well you are tolerating the medicine; your prescriber may slow that progression if side effects are noticeable. The MHRA approved a higher maintenance dose of 7.2 mg in January 2026, initially supplied as three 2.4 mg pens per week, followed by approval of a dedicated single-dose 7.2 mg pen on 14 April 2026. Whether that dose is appropriate for you is a clinical decision made at each review, not something to self-select. For a broader picture of the treatment landscape, the Wegovy overview page covers eligibility, evidence and what to expect.

The key practical point is that the pen is pre-set. You do not measure or draw up medicine. You press the pen against the injection site, press the button, and the dose is delivered. Needle disposal matters: a sharps container keeps used pens safely contained.

Once weekly, but which conditions make someone eligible?

Wegovy is licensed in the UK for adults with a BMI of 30 or above, or a BMI of 27 to 29.9 alongside at least one weight-related condition such as hypertension, dyslipidaemia, obstructive sleep apnoea, or type 2 diabetes. Lower BMI thresholds apply for some ethnic backgrounds under UK clinical guidance. A BMI figure alone does not guarantee approval; the prescriber looks at the full clinical picture, including other medicines you take and your medical history. If you are pregnant, breastfeeding, or trying to conceive, Wegovy is not recommended. It is also not licensed for anyone under 18. The Wegovy injection page sets out the eligibility criteria in more detail and explains what the consultation covers.

People sometimes ask about how Ozempic differs from Wegovy when they are weighing their options. The clinical distinction is straightforward: Ozempic is for diabetes management, not weight loss, and it is not available from a weight-loss service as a weight-loss treatment. Both are once-weekly injections of semaglutide, but they are not interchangeable from a licensing or prescribing standpoint.

What side effects come with a weekly GLP-1 injection?

Because semaglutide slows how quickly the stomach empties, gastrointestinal effects are the most commonly reported: nausea, loose stools, constipation, indigestion, and occasionally vomiting. Most people find these are sharpest in the first week or two after each dose increase, then settle. Eating smaller portions, avoiding rich or fatty food around injection day, and staying well hydrated all help. Fatigue and mild headaches are also reported, particularly early in treatment.

Rarer but serious effects include symptoms of pancreatitis, a severe, persistent stomach pain that may spread to the back. If that happens, stop and seek medical attention promptly. The MHRA Yellow Card scheme lets patients report any suspected side effect; it is worth bookmarking. On cost: if you are comparing services or thinking about what private treatment involves, a look at what Wegovy typically costs in the UK gives useful context on how private pricing is structured. And if you would like to discuss whether Wegovy is clinically right for you, starting a free consultation with our prescribers is the logical next step.